Le Lézard
Classified in: Health
Subjects: PDT, WOM

ConTIPI Medical Launches a New Website Highlighting Nonsurgical Devices for Pelvic Floor Disorders


CAESAREA, Israel, May 24, 2018 /PRNewswire/ --  ConTIPI Medical, an Israeli Medical device company, provides non-surgical and disposable vaginal solutions for women with various Pelvic Floor Disorders (PFD's). ConTIPI Medical's vaginal solutions follow a specific concept allowing women to manage their condition directly. This concept has already proved itself, brought from a design into a mature product in the market. The Impressa Device for Stress Urinary Incontinence, bought by Kimberly Clark Worldwide Inc, is marketed by Kimberly Clark Inc. under its Poise® brand (http://www.impressapro.com). ConTIPI Medical's second product, the ProVate Device, intended for the non-surgical management of Pelvic Organ Prolapse (POP) has a CE Mark for marketing in the EU and is currently within final clinical studies in the USA (considered an investigational device, limited by Federal law to investigational use).

Dr. Elan Ziv, MD, OBGYN, FPMRS, CEO & Medical Director of ConTIPI Medical

Each device comes ready for use within a wrapper, to be used by the user herself in the comfort of her home. The devices are inserted vaginally, compressed to small dimensions inside an applicator. Within the vagina, the applicator deploys the device and it opens to provide support to pre-defined specific sites along the vaginal walls. At the end of usage, the device is removed by a pull of a string, which also causes it to considerably diminish in size, and is disposed. Such devices allow women to take control over their medical problem and use them in privacy and at their convenience.

Impressa device: The Impressa device was invented by a urogynecologist in order to bridge the large gap between non-invasive and invasive treatments for Stress Urinary Incontinence in women. The device was designed to be a user friendly, disposable vaginal support, available to many women, including those who do not wish to disclose their intimate problem.  The device is available over-the-counter.

ProVate device: Most women with Pelvic Organ Prolapse will only require non-invasive management. Existing pessaries are associated with high discontinuation rate, and with high rate of reluctance to use a reusable device which is difficult for most users to insert and remove. The ProVate disposable device was designed to provide vaginal support, inserted and removed by the user at her home.

ConTIPI Medical intends to develop more solutions for other Pelvic Floor Disorders in women, following its unique design concept.

ConTIPI Medical is spearheaded by a strong management team with extensive experience and proven ability to bring a product from concept to market, and is backed by well-known consultants, in Israel and abroad. As a dedicated Research and Development (R&D) company, the entire product development process is conducted within the company.

The company's management includes Dr. Elan Ziv, MD, OBGYN, FPMRS, (CEO & Medical Director); Meital Vaknin-Shimony, B.Sc., MBA, (VP Operations) and Zohar Tyroler, B.Sc., MBA, (VP Research & Development).

ConTIPI Medical is currently launching a new website. Site address: www.contipi.com

Contact: Hofit Shalev, [email protected] 

 

SOURCE ConTIPI Medical


These press releases may also interest you

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....

at 11:16
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market...

at 11:15
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred...

at 11:10
Through its 2030 Strategic Plan, NJII plans to double the size of the organization and to exceed $70M revenue as it rolls out various new initiatives focused on accelerating technology translation, spurring innovation and upskilling workers. As...



News published on and distributed by: